Vaccines against persistent DNA virus infections

被引：5

作者：

Wills, MR ^{[1
]}

Carmichael, AJ ^{[1
]}

Sissons, JGP ^{[1
]}

机构：

[1] Univ Cambridge, Sch Clin Med, Dept Med, Cambridge, England

来源：

BRITISH MEDICAL BULLETIN | 2002年 / 62卷

关键词：

D O I：

10.1093/bmb/62.1.125

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Persistent viruses present some particular problems for vaccine design. As for acute non-persistent viruses, the prime goal of a vaccine should be to prevent primary infection. Vaccines might also be used to modify the course of established persistent virus infections - so-called postinfective immunisation. This chapter deals with selected persistent DNA viruses, in particular the human herpes viruses.

引用

页码：125 / 138

页数：14

共 53 条

[1] IMMUNITY INDUCED BY PRIMARY HUMAN CYTOMEGALOVIRUS-INFECTION PROTECTS AGAINST SECONDARY INFECTION AMONG WOMEN OF CHILDBEARING AGE [J].

ADLER, SP ;

STARR, SE ;

PLOTKIN, SA ;

HEMPFLING, SH ;

BUIS, J ;

MANNING, ML ;

BEST, AM .

JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (01) :26-32

[2] A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne) [J].

Adler, SP ;

Plotkin, SA ;

Gonczol, E ;

Cadoz, M ;

Meric, C ;

Ben Wang, JA ;

Dellamonica, P ;

Best, AM ;

Zahradnik, J ;

Pincus, S ;

Berencsi, K ;

Cox, WI ;

Gyulai, Z .

JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (03) :843-846

[3]

ASANO Y, 1994, PEDIATRICS, V94, P524

[4] COMPARATIVE-ANALYSIS OF 14 INDIVIDUAL HUMAN CYTOMEGALOVIRUS PROTEINS FOR HELPER T-CELL RESPONSE [J].

BENINGA, J ;

KROPFF, B ;

MACH, M .

JOURNAL OF GENERAL VIROLOGY, 1995, 76 :153-160

[5] A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects [J].

Berencsi, K ;

Gyulai, Z ;

Gönczöl, E ;

Pincus, S ;

Cox, WI ;

Michelson, S ;

Kari, L ;

Meric, C ;

Cadoz, M ;

Zahradnik, J ;

Starr, S ;

Plotkin, S .

JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (08) :1171-1179

[6]

BERNSTEIN DI, 1991, J IMMUNOL, V146, P3571

[7] Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells [J].

Boppana, SB ;

Britt, WJ .

VIROLOGY, 1996, 222 (01) :293-296

[8] A Genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease [J].

Boursnell, MEG ;

Entwisle, C ;

Blakeley, D ;

Roberts, C ;

Duncan, IA ;

Chisholm, SE ;

Martin, GM ;

Jennings, R ;

Challanain, DN ;

Sobek, I ;

Inglis, SC ;

McLean, CS .

JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (01) :16-25

[9] Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains [J].

Cha, TA ;

Tom, E ;

Kemble, GW ;

Duke, GM ;

Mocarski, ES ;

Spaete, RR .

JOURNAL OF VIROLOGY, 1996, 70 (01) :78-83

[10] Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection - Two randomized controlled trials [J].

Corey, L ;

Langenberg, AGM ;

Ashley, R ;

Sekulovich, RE ;

Izu, AE ;

Douglas, JM ;

Handsfield, HH ;

Warren, T ;

Marr, L ;

Tyring, S ;

DiCarlo, R ;

Adimora, AA ;

Leone, P ;

Dekker, CL ;

Burke, RL ;

Leong, WP ;

Straus, SE .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (04) :331-340

← 1 2 3 4 5 6 →